Plenary speakers

Stefanie Dimmeler

Frankfurt, Germany

Mon 8 May PATHOGENESIS OF ATHEROSCLEROSIS

RNA editing controls atherosclerosis

Dr. Dimmeler received her Ph.D. degree from the University of Konstanz/Germany. She then completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the University of Frankfurt. Since 2001 she is Professor of Experimental Medicine and since 2008 Director of the In­stitute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt. She received more than 17 awards. She presented the George E. Brown Memorial Lecture and the Paul Dudley White International Lecture at the Scientific Sessions of the AHA as well as the Thomas W. Smith Memorial Lecture and the Michael Oliver Memorial Lecture at the BAS Autumn Meeting. She received two ERC Advanced Investigator Grant. Her group elucidates the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically non-coding RNAs. 

David Erlinge

Lund, Sweden

Tue 9 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Strategies to treat vulnerable plaques

Brian A. Ference

Detroit, USA

Sun 7 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Lessons from genetics: risk-score and novel candidates

Valentin Fuster

New York, USA

Tue 9 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Imaging and CVD risk estimation (population studies)

Ulf Landmesser

Berlin, Germany

Sun 7 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Is there need to revise goals from lipid lowering

Professor Ulf Landmesser acts since October 2014 as Chairman of the Department of Cardiology at the Charité – Universitätsmedizin Berlin (CBF).

After his medical studies at the Medical School of Hannover, the University of Connecticut in Farmington (USA) and the National Heart&Lung Institute in London, he specialised in Internal Medicine and Cardiology at the Medical School of Hannover. In 2000/2001 he performed a post-doctoral fellowship at the Department of Cardiology at the Emory University School of Medicine, Atlanta (USA) as a scholar of the Alexander von Humboldt Foundation with a focus in vascular biology. He was then appointed Consultant Cardiologist at the Medical School of Hanover, Germany. In 2007, he was called as Senior Consultant Cardiologist with a focus on acute and interventional cardiology as well as on translational cardiovascular research to the Department of Cardiology at the University Hospital of Zurich, where he later acted as Vice-Chairman of the Department of Cardiology.

He received the Götz Award in 2012, the official award of the medical faculty of the University of Zurich. He serves since 2008 as Deputy Editor of the European Heart Journal.

Professor Landmesser has a particular research interest in lipids, vascular biology and coronary disease.

Peter Libby

Boston, USA

Mon 30 Nov KEYNOTE LECTURE BY PROFESSOR PETER LIBBY

Anti-inflammatory therapy and resolution of inflammation, theory and practice

Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and the Mallinckrodt Professor of Medicine at Harvard Medical School (HMS).

Dr. Libby received his medical degree from the University of California, San Diego School of Medicine. He completed a residency in internal medicine and a fellowship in cardiovascular disease at Peter Bent Brigham Hospital (now BWH). He also completed a research fellowship in cellular physiology at HMS and an honorary doctorate from the University of Lille, France Dr. Libby is board certified in internal medicine and cardiovascular disease.

Dr. Libby’s clinical and research interests include vascular biology, atherosclerosis and preventive cardiology. Dr. Libby’s research laboratory studies the messengers created by the body that may produce arterial plaque and blockages, as well as normal and abnormal function of smooth muscle and endothelial cells.

Dr. Libby has received numerous awards and recognitions for his research accomplishments, including most recently the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), and the Special Award of the Heart Failure Association of the European Society of Cardiology (2014). He has received a number of lifetime achievement awards various organizations. Dr. Libby was selected as Consulting Editor of the year by Circulation Research in 2015, and received a 2015 High Citation Award as an editorial board member of Arteriosclerosis Thrombosis, and Vascular Biology. He was awarded the Ernst Jung Gold Medal for Medicine for 2016 and the 2017 Earl Benditt Award from the North American Vascular Biology Organization. 

Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature.

He is an Editor of Braunwald’s Heart Disease, having served as the Editor-in Chief of the 8th Edition. Dr. Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 100 major named or keynote lectures throughout the world.

 

Steffen Massberg

Munich, Germany

Tue 9 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Atherothrombosis; from pathogenesis to treatment

Steffen Massberg is Professor of Cardiology and Director of the Department of Cardiology at the University Clinic Munich, Ludwig-Maximilians University in Germany.

His basic-science research topics include stem-cell biology, platelet biology, mechanisms of arterial and venous thrombosis, immune-cell migration, immune-cell/coagulation crosstalk and bio-imaging (including 2-photon microscopy). He has written over 135 articles published in national and international peer-reviewed journals, including Blood, Nature Reviews Immunology, The Journal of Experimental Medicine and Circulation.

Professor Massberg is the co-ordinator and lead scientist of the European FP7 project PRESTIGE, the co-speaker and principal investigator of the DFG Collaborative Research Unit (SFB) 914 and the principal investigator of the DFG-Research Unit (FOR) 923. He has received many prizes for his work, the most recent being the 2011 Martin Villar Haemostasis Award (together with Dr Bernd Engelmann) and the 2012 Basic Science Award from the German Society of Cardiology (DGK).

Gerard Pasterkamp

Utrecht, The Netherlands

Mon 8 May PATHOGENESIS OF ATHEROSCLEROSIS

Shifting concepts in the description of the "vulnerable plaque"

Gerard Pasterkamp, MD, is Professor of the laboratory of clinical chemistry at the University Medical Center Utrecht. His research interests are in the field of cardiovascular biology and innovation in biomarkers and drug targets to diagnose and treat atherosclerotic disease. The research group houses the largest atherosclerotic plaque biobank worldwide: Athero Express including >4500 patients. This biobank has generated new insights into determinants of plaque destabilisation. The laboratory also invests in the excavation of genetic determinants of atherosclerotic plaque characteristics. He has coordinated national and EU based consortia with the aim to unravel biomarkers and mechanisms of atherosclerotic disease.

Yusuf Salim

Hamilton, USA

Sun 7 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Lessons from epidemiology and environmental CVD risk factors

Ira Tabas

New York, USA

Mon 8 May PATHOGENESIS OF ATHEROSCLEROSIS

Defective inflammatory resolution in atherosclerosis: Mechanisms and therapeutic opportunities

Dr. Tabas, Richard J. Stock Professor of Medicine, Columbia University, completed his M.D./Ph.D. at Washington University and his clinical training at Columbia. His research has elucidated signaling pathways in macrophages that contribute to atherosclerosis and in hepatocytes that contribute to pro-atherogenic insulin resistance. His papers have appeared in Cell, Nature, Science, Nature Cell Biology, Cell Metabolism and other top journals, and he is on Science’s Board of Reviewing Editors. His awards include election to ASCI/AAP, AHA Established Investigator Award, Columbia University Lamport Research Award, AHA/ATVB Council Special Recognition Award, Washington University Alumni Achievement Award, the Society of Leukocyte Biology Bonazinga award, the Harrington Discovery Institute Innovator-Scholar Award, and the AHA Ross Lectureship Award.

Marja-Riitta Taskinen

Helsinki, Finland

Mon 30 Nov KEYNOTE LECTURE BY PROFESSOR MARJA-RIITTA TASKINEN

Disturbances in hepatic and lipoprotein metabolism is the hallmark of atherogenic dyslipidemia

Marja-Riitta Taskinen MD, PhD and Emerita Professor of Medicine and her team is a member of the Research Program Unit, Diabetes & Obesity Research program at the University of Helsinki. Her research team at Biomedicum Helsinki focuses on lipoprotein kinetics in health and metabolic disorders including diabetes and dyslipidemias and genetics of familial dyslipidemias.

She has about 430 original publications and about 130 reviews and chapters (H-index 85). Her outstanding achievements have been recognized by several international awards including the Claude Bernard Award (EASD 2002), Edwin Bierman Award (ADA 2004) and Novartis Award (2006). She has been involved in activities of European Atherosclerosis Society (President of EAS 2006-2008) and IAS (International Atherosclerosis Society) as well as of the EASD and IDF (International Diabetes Federation). The Finnish Medical Foundation chose her as the winner of the Pohjola and Suomi Mutual Medical Award for 2012. She is a member of the EAS/ESC Guidelines committee on Management of dyslipidemias and member of EAS Consensus Paper Panel.

Viola Vaccarino

Atlanta, USA

Sun 7 May RISK FACTORS AND PREDICTORS FOR CARDIOVASCULAR DISEASE

Stress, behavior and cardiovascular disease

Viola Vaccarino, M.D., Ph.D., is the Wilton Looney Chair of Cardiovascular Research, Professor of Epidemiology and Medicine, and Chair of the Department of Epidemiology at Emory University in Atlanta, USA. She received an M.D. from the University of Milan, Italy, and a Ph.D. in Epidemiology from Yale University. She is a recognized leader on mind-body relationships in heart disease and on the role of psychological stress, mental health and behavioral factors on cardiovascular risk. Dr. Vaccarino is the author of over 300 peer-reviewed research publications and has an extensive record of research funding from the National Institutes of Health.

Renu Vimani

Gaithersburg, USA

Mon 8 May PATHOGENESIS OF ATHEROSCLEROSIS

Neoatherosclerosis from a pathologist's point of view

Joseph Witztum

San Diego, USA

Tue 9 May STRATEGIES TO DETECT AND TREAT ATHEROSCLEROSIS

Novel theraeutic approaches using antisense inhibition

Joseph L. Witztum, MD has worked in the field of lipoprotein metabolism and atherogenesis for almost forty years, and currently is Distinguished Professor of Medicine at the University of California, San Diego. His basic work has provided an improved understanding of the role of oxidized LDL and immunological mechanisms in atherogenesis and clinically, he has promoted the development of novel therapies for unmet needs, especially in the context of hypertriglyceridemia and elevated Lp(a) levels. He has published more than 430 manuscripts and has been an Editor of major scientific journals in the field for the past 30 years.